Evolent Q3 Adj EBITDA $39M (8.1% margin); new CFO Ramos; 2026 revenue forecast $2.5B

Evolent Health, Inc.

2025-Q3 EPS reported -$1.31 revenue$1,407,510,000

Q3 revenue $479.5M, net loss $26.9M; adjusted EBITDA $39.0M vs $31.8M YoY.
Two new customer agreements bring YTD total to 13; >$750M new annualized revenue to launch in 2026.
Mario Ramos appointed CFO effective Jan 1, 2026; John Johnson becomes Chief Strategy Officer.
New CFO Ramos receives $550K base salary, $625K bonus, $100K sign-on bonus, and $2.35M RSU grant.
Katie DiPerna named COO; Emily Rafferty transitions to EVP Customer Success.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.